The FDA approved ciltacabtagene autoleucel for earlier use in certain adults with relapsed or refractory multiple myeloma.
The expanded indication permits treatment with the chimeric antigen receptor T cells after first relapse and applies to adults who are refractory to lenalidomide and have received at least one previous line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech), also referred to as cilta-cel, is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy previously approved for use in
